Latigo Biotherapeutics, Inc. Common Stock (LTGO) FinancialsLTGOLatigo Biotherapeutics, Inc. Common Stock

In the context of the broader market, LTGO competes directly with industry leaders such as MLTX and MNKD. With a market capitalization of $1.05B, it holds a significant position in the sector. When comparing efficiency, LTGO's gross margin of N/A stands against MLTX's N/A and MNKD's 69.00%. Such benchmarking helps identify whether Latigo Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Latigo Biotherapeutics has reported negative earnings consistently, with a net income of -25,797,000 USD in Q2 2026. The current ratio is 1.15, indicating adequate short-term liquidity, but the debt to equity ratio is concerning at 239.14%.